{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:36Z","timestamp":1740120096093,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870109","82070149"],"award-info":[{"award-number":["81870109","82070149"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202191"],"award-info":[{"award-number":["7202191"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12185-022-03298-9","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T17:02:21Z","timestamp":1644166941000},"page":"713-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT"],"prefix":"10.1007","volume":"115","author":[{"given":"Ning","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ji","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2035-7472","authenticated-orcid":false,"given":"Xiao-Ning","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,6]]},"reference":[{"issue":"11","key":"3298_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","volume":"53","author":"M Horowitz","year":"2018","unstructured":"Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018;53(11):1379\u201389.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"3298_CR2","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41409-020-01163-z","volume":"56","author":"M Yanada","year":"2021","unstructured":"Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2021;56(5):1126\u201333.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"3298_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.bbmt.2010.04.004","volume":"16","author":"SZ Pavletic","year":"2020","unstructured":"Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the epidemiology and natural history of relapse following allogeneic cell transplantation. Biol Blood Marrow Transplant. 2020;16(7):871\u201390.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"3298_CR4","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","volume":"119","author":"CH Yan","year":"2012","unstructured":"Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256\u201362.","journal-title":"Blood"},{"issue":"3","key":"3298_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3324\/haematol.10570","volume":"92","author":"XJ Huang","year":"2007","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92(3):414\u20137.","journal-title":"Haematologica"},{"issue":"3","key":"3298_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bbmt.2013.11.020","volume":"20","author":"AM Zeidan","year":"2014","unstructured":"Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014;20(3):314\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"3298_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","volume":"4","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4(9):1245\u201353.","journal-title":"JAMA Oncol"},{"issue":"4","key":"3298_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/bjh.14923","volume":"79","author":"Y Chen","year":"2017","unstructured":"Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017;79(4):598\u2013605.","journal-title":"Br J Haematol"},{"issue":"1","key":"3298_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00277-018-3482-7","volume":"98","author":"XN Gao","year":"2019","unstructured":"Gao XN, Lin J, Wang SH, Huang WR, Li F, Li HH, et al. Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies. Ann Hematol. 2019;98(1):185\u201393.","journal-title":"Ann Hematol"},{"issue":"5","key":"3298_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00277-019-03636-8","volume":"98","author":"XN Gao","year":"2019","unstructured":"Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, et al. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia. Ann Hematol. 2019;98(5):1267\u201377.","journal-title":"Ann Hematol"},{"issue":"4","key":"3298_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855\u201364.","journal-title":"Br J Haematol"},{"issue":"31","key":"3298_CR12","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"C Schmid","year":"2007","unstructured":"Schmid C, Labopin M, Nagler A, Bornh\u00e4user M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol. 2007;25(31):4938\u201345.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3298_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453\u201374.","journal-title":"Blood"},{"issue":"2","key":"3298_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419\u201325.","journal-title":"Blood"},{"issue":"5","key":"3298_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3298_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"4","key":"3298_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","volume":"21","author":"T Schroeder","year":"2015","unstructured":"Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2013a retrospective multicenter analysis from the German cooperative transplant study group. Biol Blood Marrow Transplant. 2015;21(4):653\u201360.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"3298_CR18","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3298_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40(4):381\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"3298_CR20","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/bmt.2009.359","volume":"45","author":"L Scrucca","year":"2010","unstructured":"Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45(9):1388\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"3298_CR21","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3389\/fimmu.2019.02516","volume":"10","author":"YJ Chang","year":"2019","unstructured":"Chang YJ, Zhao XY, Huang XJ. Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation. Front Immunol. 2019;10:2516.","journal-title":"Front Immunol"},{"issue":"11","key":"3298_CR22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"A Takami","year":"2014","unstructured":"Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the adult acute myeloid leukemia working group of the Japan society for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785\u201390.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"3298_CR23","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","volume":"119","author":"C Schmid","year":"2012","unstructured":"Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599\u2013606.","journal-title":"Blood"},{"issue":"3","key":"3298_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"3298_CR25","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/ctr.12561","volume":"29","author":"CH Yan","year":"2015","unstructured":"Yan CH, Xu LP, Liu DH, Chen H, Wang Y, Wang JZ, et al. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT. Clin Transplant. 2015;29(7):594\u2013605.","journal-title":"Clin Transplant"},{"issue":"6","key":"3298_CR26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1399-0012.2012.01618.x","volume":"26","author":"CH Yan","year":"2012","unstructured":"Yan CH, Liu DH, Xu LP, Liu KY, Zhao T, Wang Y, et al. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant. 2012;26(6):868\u201376.","journal-title":"Clin Transplant"},{"issue":"8","key":"3298_CR27","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.bbmt.2019.04.018","volume":"25","author":"L Xuan","year":"2019","unstructured":"Xuan L, Wang Y, Chen J, Jiang E, Gao L, Wu B, et al. Sorafenib therapy is associated with Improved outcomes for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(8):1674\u201381.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"3298_CR28","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1038\/s41409-021-01416-5","volume":"56","author":"A Zucenka","year":"2021","unstructured":"Zucenka A, Vaitekenaite V, Maneikis K, Davainis L, Pileckyte R, Trociukas I, et al. Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2021;56(11):2804\u201312.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"3298_CR29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.bbmt.2020.02.006","volume":"26","author":"S Schmidt","year":"2020","unstructured":"Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, et al. The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era. Biol Blood Marrow Transplant. 2020;26(6):1137\u201343.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"3298_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew NR, Baumgartner F, Braun L, O\u2019Sullivan D, Thomas S, Waterhouse M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282\u201391.","journal-title":"Nat Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03298-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T15:50:06Z","timestamp":1651074606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03298-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,6]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3298"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03298-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,2,6]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}